Frontlight ResearchEarly access
Taking people in United StatesPhase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Key facts
- Who runs it
- Axsome Therapeutics, Inc.
- Where
- Allentown, Austin, Boston, Cherry Hill, Cincinnati, Clermont, Colorado Springs, Cromwell, Dallas, Draper, Encino, Fort Myers, Garden Grove, Greenville, Jacksonville, Lauderhill, Long Beach, Marietta, Mason, Media, Memphis, Methuen, Miami, Miami Lakes, Middleburg Heights, Mission Viejo, Mount Kisco, New York, North Canton, North Charleston, Orlando, Overland Park, Portland, Princeton, Raleigh, Saint Charles, San Antonio, San Diego, Santa Ana, Walnut Creek, and West Covina, United StatesSee the 41 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 450 people, planned
- Started
- 26 Apr 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Solriamfetol 150 mg
- Solriamfetol 300 mg
- Placebo
- Record updated
- 28 July 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Primary diagnosis of BED according to DSM-5 criteria
- Provides written informed consent to participate in the study before the conduct of any study procedures
- Male or female, aged 18 to 55 inclusive
Who cannot take part
- Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription
- Unable to comply with study procedures
- Medically inappropriate for study participation in the opinion of the investigator
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- Allentown, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
- Austin, TexasHospital not named in the registryContact: Study DirectorTaking people
- Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
- Cherry Hill, New JerseyHospital not named in the registryContact: Study DirectorTaking people
- Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
- Clermont, FloridaHospital not named in the registryContact: Study DirectorNo longer taking part
- Colorado Springs, ColoradoHospital not named in the registryContact: Study DirectorTaking people
- Cromwell, ConnecticutHospital not named in the registryContact: Study DirectorTaking people
- Dallas, TexasHospital not named in the registryContact: Study DirectorTaking people
- Draper, UtahHospital not named in the registryContact: Study DirectorNo longer taking part
- Encino, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Fort Myers, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Garden Grove, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Greenville, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Jacksonville, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Lauderhill, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Long Beach, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Marietta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
- Mason, OhioHospital not named in the registryContact: Study DirectorTaking people
- Media, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
- Memphis, TennesseeHospital not named in the registryContact: Study DirectorTaking people
- Methuen, MassachusettsHospital not named in the registryContact: Study DirectorNo longer taking part
- Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Miami Lakes, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Middleburg Heights, OhioHospital not named in the registryContact: Study DirectorTaking people
- Mission Viejo, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Mount Kisco, New YorkHospital not named in the registryContact: Study DirectorTaking people
- New YorkHospital not named in the registryContact: Study DirectorTaking people
- North Canton, OhioHospital not named in the registryContact: Study DirectorNo longer taking part
- North Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Orlando, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Overland Park, KansasHospital not named in the registryContact: Study DirectorTaking people
- Portland, OregonHospital not named in the registryContact: Study DirectorTaking people
- Princeton, New JerseyHospital not named in the registryContact: Study DirectorTaking people
- Raleigh, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Saint Charles, MissouriHospital not named in the registryContact: Study DirectorTaking people
- San Antonio, TexasHospital not named in the registryContact: Study DirectorTaking people
- San Diego, CaliforniaHospital not named in the registryContact: Study DirectorNo longer taking part
- Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Walnut Creek, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- West Covina, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
About the trial
What the trial wants to find out
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
The 3 groups in the trial
- Solriamfetol 150 mgTreatment being tested
Up to 12 weeks
- Solriamfetol 300 mgTreatment being tested
Up to 12 weeks
- PlaceboPlacebo, for comparison
Up to 12 weeks
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)
- Fit questions
- Built from NCT06413433, who can take part
- Record updated
- 28 July 2026